ALPNALPINE IMMUNE SCIENCES, INC.

Nasdaq alpineimmunesciences.com


$ 64.94 $ 0.12 (0.19 %)    

Friday, 10-May-2024 15:59:56 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 64.94
$ 64.94
$ 0.00 x 0
$ 0.00 x 0
$ 64.92 - $ 64.94
$ 7.71 - $ 64.94
3,047,933
na
4.16B
$ 1.01
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 03-19-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-23-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 08-10-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-18-2021 12-31-2020 10-K
15 11-12-2020 09-30-2020 10-Q
16 08-11-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 11-14-2019 09-30-2019 10-Q
20 08-13-2019 06-30-2019 10-Q
21 05-09-2019 03-31-2019 10-Q
22 03-18-2019 12-31-2018 10-K
23 11-08-2018 09-30-2018 10-Q
24 08-09-2018 06-30-2018 10-Q
25 05-14-2018 03-31-2018 10-Q
26 03-28-2018 12-31-2017 10-K
27 11-14-2017 09-30-2017 10-Q
28 07-21-2017 06-30-2017 10-Q
29 05-02-2017 03-31-2017 10-Q
30 02-13-2017 12-31-2016 10-K
31 11-07-2016 09-30-2016 10-Q
32 08-02-2016 06-30-2016 10-Q
33 05-03-2016 03-31-2016 10-Q
34 03-08-2016 12-31-2015 10-K
35 11-03-2015 09-30-2015 10-Q
36 08-04-2015 06-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 alpine-immune-sciences-q1-eps-028-beats-041-estimate-sales-703m-beat-352m-estimate

Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate o...

 100b-vertex-pharma-working-to-recreate-10b-cystic-fibrosis-success---this-time-focused-on-pain-management-drugs

Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising...

 td-cowen-downgrades-alpine-immune-sciences-to-hold

TD Cowen analyst Boris Peaker downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Buy to Hold.

 leerink-partners-downgrades-alpine-immune-sciences-to-market-perform-raises-price-target-to-65

Leerink Partners analyst Thomas Smith downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Outperform to Market Perform and ...

 vertexs-alpine-acquisition-unpacking-analyst-predictions-on-povetacicepts-potential-impact

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-media...

 stocks-bounce-back-with-tech-gold-gaining-after-modest-producer-inflation-data-whats-driving-markets-thursday

Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly low...

 why-fastenal-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter f...

 enliven-therapeutics-alpine-immune-sciences-janux-therapeutics-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NA...

 vertex-pharmaceuticals-moves-beyond-10b-cystic-fibrosis-franchise-pays-around-5b-for-kidney-disease-player-alpine-immune

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BA...

 wedbush-downgrades-alpine-immune-sciences-to-neutral

Wedbush analyst Robert Driscoll downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Outperform to Neutral.

 wolfe-research-downgrades-alpine-immune-sciences-to-peer-perform

Wolfe Research analyst Andy Chen downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Outperform to Peer Perform.

 wall-street-braces-for-another-red-day-ahead-of-more-inflation-data-while-bitcoin-holds-above-70k-analyst-sees-any-pullback-as-phenomenal-buying-opportunity

The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have signif...

 rbc-capital-downgrades-alpine-immune-sciences-to-sector-perform-raises-price-target-to-65

RBC Capital analyst Gregory Renza downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Outperform to Sector Perform and rais...

 why-rallybio-shares-are-trading-higher-by-around-78-here-are-20-stocks-moving-premarket

Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collabo...

 morgan-stanley-downgrades-alpine-immune-sciences-to-equal-weight-raises-price-target-to-65

Morgan Stanley analyst Michael Ulz downgrades Alpine Immune Sciences (NASDAQ:ALPN) from Overweight to Equal-Weight and raise...

 why-bitcoin-linked-microstrategy-along-with-adial-pharmaceuticals-alpine-immune-sciences-marin-software-and-tesla-are-on-investors-radars-today

On Wednesday, key U.S. stock indexes closed lower, as the Dow Jones Industrial Average fell by 1.1% to 38,461.51, the S&P 5...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION